Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humans.
Eduardo Cararo LopesAkshada SawantDirk MooreHua KeFuqian ShiSaurabh LaddhaYing ChenAnchal SharmaJake NaumannJessie Yanxiang GuoMaria GomezMaria IbrahimTracey L SmithGregory M RiedlingerEdmund C LattimeStanley TrooskinShridar GanesanXiaoyang SuRenata PasqualiniWadih ArapSubhajyoti DeChang S ChanEileen WhitePublished in: medRxiv : the preprint server for health sciences (2023)
In this article, we propose a new integrated metabolic, genomic, and cytopathologic methods to diagnose Differentiated Thyroid Cancer when the conventional methods failed. Moreover, we suggest metabolic and genomic markers to help predict high-risk Papillary Thyroid Cancer. Both might be important tools to avoid unnecessary surgery and/or radioiodine therapy that can worsen the quality of life of the patients more than living with an indolent Thyroid nodule.
Keyphrases
- end stage renal disease
- ejection fraction
- minimally invasive
- chronic kidney disease
- small cell lung cancer
- squamous cell carcinoma
- copy number
- peritoneal dialysis
- prognostic factors
- coronary artery bypass
- stem cells
- gene expression
- young adults
- climate change
- patient reported
- risk assessment
- squamous cell
- childhood cancer
- genome wide
- percutaneous coronary intervention